Shots:
- The CHMP has recommended Capvaxive for active immunization against invasive disease & pneumonia caused by Streptococcus pneumoniae in adults (≥18yrs.), with the EC’s decision expected in Q2’25 for EU, Iceland, Liechtenstein and Norway. Ongoing regulatory review in Japan, plus multiple filings are underway
- Opinion was backed by P-III (STRIDE-3) data, assessing Capvaxive vs PCV20 in pneumococcal vaccine-naïve adults (≥18yrs.), plus data from various P-III trials (STRIDE-4, STRIDE-5, STRIDE-6, STRIDE-7, & STRIDE-10) assessing it in both vaccine-naïve & vaccinated adults
- Capvaxive (single dose) targets Streptococcus pneumoniae serotypes against IPD in adults, incl. 8 unique serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31, 35B)
Ref: Merck | Image: Merck
Related News:- Merck Reports the US FDA’s BLA Acceptance of Clesrovimab to Protect Infants from RSV Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
